PubRank

M Wernli

Author PubWeight™ 33.88‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998 3.21
2 Ultraviolet light downregulates CD95 ligand and TRAIL receptor expression facilitating actinic keratosis and squamous cell carcinoma formation. J Invest Dermatol 2001 1.54
3 Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006 1.41
4 Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005 1.36
5 Medication errors in chemotherapy: incidence, types and involvement of patients in prevention. A review of the literature. Eur J Cancer Care (Engl) 2009 1.20
6 A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 2005 1.20
7 Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: multicentre study with multiple and novel assays. J Med Virol 2001 1.10
8 Green fluorescent protein as a novel tool to measure apoptosis and necrosis. Cytometry 2001 1.10
9 Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis. Oncogene 2008 1.08
10 In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology 1998 1.04
11 Dicentric translocation (9;12) presenting as refractory Philadelphia chromosome-positive acute B-cell lymphoblastic leukemia. Cancer Genet Cytogenet 1999 0.98
12 The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000 0.97
13 Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. Br J Cancer 2004 0.93
14 Barriers and facilitators to chemotherapy patients' engagement in medical error prevention. Ann Oncol 2010 0.92
15 Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. Blood 1988 0.88
16 Down-modulation of CD4+ T helper type 2 and type 0 cells by T helper type 1 cells via Fas/Fas-ligand interaction. Eur J Immunol 1995 0.86
17 Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2005 0.86
18 Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol 2002 0.85
19 Evaluation of the Sysmex R-1000. An automated reticulocyte analyzer. Am J Clin Pathol 1990 0.85
20 Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. J Clin Invest 1997 0.84
21 High human herpesvirus 8 seroprevalence in the homosexual population in Switzerland. J Clin Microbiol 1998 0.82
22 Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study. Support Care Cancer 1995 0.81
23 Multicenter evaluation of new double-antigen sandwich enzyme immunoassay for measurement of anti-human immunodeficiency virus type 1 and type 2 antibodies. J Clin Microbiol 1996 0.81
24 Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland. BJU Int 2003 0.81
25 Changes in the connective tissue proteins, glycosaminoglycans and calcium in the arteries of the cynomolgus monkey during atherosclerotic induction and regression. Atherosclerosis 1984 0.81
26 Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001 0.81
27 Efficient mobilization of PBSC with vinorelbine/G-CSF in patients with malignant lymphoma. Bone Marrow Transplant 2009 0.80
28 Effect of antiretroviral therapy on apoptosis markers and morphology in peripheral lymph nodes of HIV-infected individuals. Infection 2008 0.80
29 Training workers at risk for occupational contact dermatitis in the application of protective creams: efficacy of a fluorescence technique. Dermatology 1997 0.79
30 The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer 1998 0.79
31 Self-application of a protective cream. Pitfalls of occupational skin protection. Arch Dermatol 1997 0.79
32 [Cerebral metastasis in choriocarcinoma a case report]. Praxis (Bern 1994) 2003 0.78
33 Fas-ligand gene silencing in basal cell carcinoma tissue with small interfering RNA. Gene Ther 2005 0.78
34 Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. Bone Marrow Transplant 2003 0.78
35 Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study. Eur J Cancer 2002 0.78
36 Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. Br J Cancer 2006 0.77
37 [Emergency therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF)]. Schweiz Med Wochenschr 1991 0.75
38 [Immunoglobulin deficiency after repeated plasmapheresis]. Schweiz Med Wochenschr 1991 0.75
39 Flow cytometric monitoring of parasitaemia during treatment of severe malaria by exchange transfusion. Eur J Haematol 1991 0.75
40 A microtechnique for the rapid determination of the glycosaminoglycans of vascular tissues. Anal Biochem 1982 0.75
41 Prostate cancer screening: results of a prospective trial in Canton Aargau, Switzerland. Swiss Med Wkly 2004 0.75
42 Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1998 0.75
43 [Risk factors in diagnostic and therapeutic use of ERCP]. Schweiz Rundsch Med Prax 1984 0.75
44 [Autologous transplantation of hematopoietic precursor cells following CD34 selection]. Schweiz Med Wochenschr 1996 0.75
45 [What is your diagnosis? Coumarin necrosis]. Praxis (Bern 1994) 2004 0.75
46 An intra-operative seminal and prostate emission test as a control for nerve-sparing procedures in primary and secondary retroperitoneal lymphadenectomy. Br J Urol 1996 0.75
47 Bone marrow transplantation in Basel: single center experience from 1973 to 1989. Clin Transpl 1989 0.75
48 [Sense and usefulness of preventive diagnosis]. Ther Umsch 1994 0.75
49 [Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a]. Schweiz Med Wochenschr 1989 0.75
50 Autologous bone marrow transplantation for recurrent malignant lymphoma after liver transplantation. Transplantation 1999 0.75
51 [Cervical tuberculous lymphadenopathy--a rare complication of myelodysplastic syndrome]. Praxis (Bern 1994) 2001 0.75
52 Sampling bias and logistical problems of molecular analyses in a clinical leukaemia trial. Swiss Group for Clinical Cancer Research (SAKK) Br J Haematol 1998 0.75
53 Human immunodeficiency and hepatitis C virus coinfection influenced by interferon-gamma. Immunol Lett 2000 0.75